Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 71 for:    GALE

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02125318
Recruitment Status : Completed
First Posted : April 29, 2014
Last Update Posted : February 27, 2017
Sponsor:
Information provided by (Responsible Party):
Galena Biopharma, Inc.

Brief Summary:

Anagrelide is a drug that has been shown to slow down how fast platelets are made in the bone marrow, and has been approved by the FDA for treating high platelets counts in patients with bone marrow disorders.

Anagrelide Controlled Release ("CR") is a new preparation of anagrelide that is made to dissolve more slowly than currently marketed versions of this drug. Because of this, the anagrelide is taken up into the blood more slowly. Researchers think that this slower release of the drug could help to lower side effects that might be caused by high blood levels when the drug dissolves as quickly as it does with the currently marketed product.

The main purposes of this study are to see how well Anagrelide CR can control platelet counts in patients with high platelet levels, to see what kind of side effects it causes, and to measure blood levels of the drug.


Condition or disease Intervention/treatment Phase
Thrombocytosis Myeloproliferative Neoplasms Drug: Anagrelide CR Phase 2

Detailed Description:

This is an open-label, single-arm, multicenter, Phase 2 study of anagrelide CR in subjects with an MPN-related thrombocytosis. Eligible subjects will include those who have not been previously treated for thrombocytosis or have not received platelet-lowering therapy for at least 2 weeks prior to study treatment. Each subject will receive anagrelide CR at a starting dose of 0.5 mg b.i.d. (1.0 mg/day), and is anticipated to continue study treatment for at least 24 weeks. Subjects who have achieved clinical benefit in the opinion of the Investigator and who are tolerating the study drug may continue study treatment until they develop unacceptable toxicity or other discontinuation criteria have been met.

The primary efficacy endpoint will be the proportion of subjects who achieve a platelet response (CR or PR). The safety and tolerability of study treatment will be assessed by the frequency and severity of adverse events as determined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. The PK profile of anagrelide CR will be assessed at the initial (0.5mg b.i.d.) and final titrated dose levels.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)
Study Start Date : May 2014
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016


Arm Intervention/treatment
Experimental: Anagrelide CR (GALE-401) Drug: Anagrelide CR
Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
Other Name: GALE-401




Primary Outcome Measures :
  1. Platelet Response [ Time Frame: Up to 24 weeks ]

    The primary efficacy endpoint will be the proportion of subjects who achieve a platelet response (complete or partial response), with response defined according to the following criteria:

    • Complete response (CR): platelet count of ≤400 x 10e9/L maintained for at least 4 weeks
    • Partial response (PR): a platelet count of ≤600 x 10e9/L or a ≥50% reduction from baseline and maintenance of the reduction for at least 4 weeks
    • Nonresponse: failure to meet CR or PR criteria


Secondary Outcome Measures :
  1. Number of subjects with adverse events [ Time Frame: Throughout study treatment (expected average of 12 months) ]
    Frequency and severity of adverse events as determined by NCI CTCAE (v 4.03).

  2. Plasma concentrations of anagrelide [ Time Frame: Up to 13 weeks ]
    Monitor anagrelide levels during dose titration and assess pharmacokinetic profile at starting and final dose levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide written informed consent prior to any study specific procedure
  2. Male or female patients aged ≥ 18 years
  3. Diagnosis of a myeloproliferative neoplasm (i.e., chronic myelogenous leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET)) as determined by the treating physician, such as based on the 2008 World Health Organization (WHO) classification of myeloid malignancies
  4. Baseline platelet count ≥600 x 10e9/L as determined on two occasions at least 14 days apart prior to the first dose of study drug
  5. Requirement for platelet reduction therapy as assessed by the Investigator
  6. Currently not receiving therapy specifically intended to reduce platelet counts
  7. For patients with ET, prior platelet lowering therapy (e.g., hydroxyurea, anagrelide or interferon) may not be administered within 2 weeks prior to the first dose of study drug.

    For patients with MPN diagnoses other than ET, concurrent anti-MPN treatment is permitted provided that the treatment has been administered at stable doses for at least 4 weeks prior to the first dose of study drug. Examples of permitted medications include but are not limited to hydroxyurea for PV, ruxolitinib for MF, and imatinib for CML. All patients must have discontinued anagrelide at least 2 weeks prior to the first dose of study drug.

    EXCEPTION: busulfan, melphalan and phosphate P-32 must have been discontinued at least 4 weeks prior to the first dose of study drug.

  8. Adequate hepatic function defined as bilirubin ≤1.5 x ULN, INR ≤1.5 x ULN, albumin >3.5 g/dL, ALT < 3.0 x ULN, AST < 3.0 x ULN
  9. If female, must be of non-childbearing potential, i.e. post- menopausal (defined as > 12 months since last menstrual period) or surgically sterilized (i.e. tubal ligation or hysterectomy at least 6 months prior to screening) or, if of childbearing potential, must not be pregnant or nursing
  10. Males and females of child bearing must agree to use an acceptable form of birth control until 28 days following the last dose of study drug

Exclusion Criteria:

  1. Other MPN diagnoses not specifically included above: Chronic neutrophilic leukemia, chronic eosinophilic leukemia, mastocytosis, and unclassifiable MPNs
  2. Previously found to be refractory to anagrelide therapy (i.e., failure to achieve a platelet count <600 x 10e9/L for reasons other than anagrelide-related toxicity)
  3. History of coronary artery disease requiring a revascularization procedure within 3 months prior to screening
  4. Left bundle branch block or sustained ventricular tachycardia (>30 seconds) evident on 12-lead ECG at screening
  5. Tachycardia defined as resting heart rate >100 bpm at screening
  6. Unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, or prolonged duration) within 3 months prior to screening
  7. Transient ischemic attack (TIA) or stroke within 3 months prior to screening
  8. Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a subject and/or their compliance with the protocol.
  9. Current alcohol or drug abuse, or a significant medical condition that, in the opinion of the Investigator, may impair compliance with the requirements of the protocol
  10. History of allergic hypersensitivity to anagrelide or any component of its formulations
  11. Administration of Type 3 phosphodiesterase (PDE3) inhibitors (e.g., inamrinone, cilostazol, milrinone) within 2 weeks prior to initiating study treatment
  12. Administration of any investigational product within 4 weeks prior to initiating study treatment
  13. History of intolerance of other PDE3 inhibitors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02125318


Locations
Layout table for location information
United States, California
East Valley Hematology and Oncology Medical Group
Burbank, California, United States, 91505
California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, United States, 92024
California Cancer Associates for Research & Excellence (cCARE)
Escondido, California, United States, 92025
California Cancer Associates For Research and Excellence
Fresno, California, United States, 93720
United States, Florida
Innovative Medical Research of South Florida, Inc.
Aventura, Florida, United States, 33180
United States, Kansas
Cancer Center of Kansas
Wichita, Kansas, United States, 67214
United States, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
Gettysburg Cancer Center
Gettysburgh, Pennsylvania, United States, 17325
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Cancer Care Centers of South Texas
New Braunfels, Texas, United States, 78130
Cancer Care Centers of South Texas
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Galena Biopharma, Inc.

Layout table for additonal information
Responsible Party: Galena Biopharma, Inc.
ClinicalTrials.gov Identifier: NCT02125318     History of Changes
Other Study ID Numbers: GALE-401-201
First Posted: April 29, 2014    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: February 2017

Keywords provided by Galena Biopharma, Inc.:
myeloproliferative neoplasm
chronic myelogenous leukemia
polycythemia vera
primary myelofibrosis
essential thrombocythemia
anagrelide
thrombocytosis
GALE-401

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Myeloproliferative Disorders
Thrombocythemia, Essential
Thrombocytosis
Bone Marrow Diseases
Hematologic Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hemorrhagic Disorders
Anagrelide
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors